The cDNAs for two separate human 17 beta-hydroxysteroid dehydrogenases (17 beta-HSD) have been isolated and sequenced. The well-studied human placental cytosolic 17 beta-HSD (also referred to as estradiol dehydrogenase) preferentially catalyzes the reduction of estrone to estradiol-17 beta and the reduction of the C-20-ketone of progesterone to 20 alpha-dihydroprogesterone. This isoform of the enzyme has been referred to as 17 beta-HSD type 1 and localized to chromosome 17. A second 17 beta-HSD isoform (referred to as type 2) is localized in the endoplasmic reticulum of human trophoblast and is characterized by the preferential oxidation of the C-17 beta-hydroxyl group of C18-and C19-steroids and the C-20 alpha-hydroxyl group of 20 alphadihydroprogesterone. In this study, we determined the chromosomal localization of human 17 beta-HSD type 2, the expression of this gene in human endometrium, and the tissue distribution of the mRNA. We found that the human 17 beta-HSD type 2 gene is localized on chromosome 16, 16q24. 17 beta-HSD type 2 mRNA (approximately 1.5 kb) was identified in human endometrial tissues by Northern analysis of total RNA (10 micrograms). The highest levels of 17 beta-HSD type 2 mRNA were found in endometrial tissues obtained during the mid-to late secretory phase of the ovarian cycle (i.e., during the time of high plasma levels of progesterone 
Introduction
It is established that estradiol-17,6, and not estrone, is the principal estrogen secreted by the human placenta (see reference 1), ovary (see reference 2), and testis (3) . Also, testosterone (and not androstenedione) is secreted by the adult human testis (3), and progesterone (and not 20a-dihydroprogesterone) is the primary C21-steroid secreted by human placenta (1) and corpus luteum (4) . The adrenal cortex, and most tumors of the adrenal, secrete androstenedione (but not testosterone) and small amounts of progesterone but little or no 20a-dihydroprogesterone (5, 6) . Contrarily, many extraglandular tissues preferentially convert estradiol-17,3 to estrone, testosterone to androstenedione, and progesterone to 20a-dihydroprogesterone (5, (7) (8) (9) . It is unlikely that this anatomical distribution of 17/3-hydroxysteroid (17/3-HSD)l and 20a-hydroxysteroid oxidation/reduction activities, favoring C-17 and C-20 reduction in some tissues and oxidation in others can be accounted for by the redox potential of a given cell. Rather, it is much more likely that this difference in sex steroid hormone synthesis and metabolism is attributable to tissue-specific expression of isozymes that catalyze the 17/-oxidation-reduction of C19-and C18-steroids and the 20a-oxidation-reduction of progesterone, in a manner similar to that now recognized for the 3,6-hydroxysteroid dehydrogenase family of enzymes (10) . A number of investigators have deduced, therefore, that there must be multiple 17fi-HSDs, some of which also are capable of C-20a-oxidoreduction.
In human placenta, the cytosolic isoform of 17,/-HSD, most recently referred to as 17/3-HSD type 1 (11) , is most efficient in the reduction of estrone to estradiol-17/3 and much less effective in 17/3-oxidation-reduction of C19-steroids. A cDNA for this enzyme has been isolated and sequenced by several groups of investigators (12) (13) (14) . Thus, the placental cytosolic 17,/-HSD enzyme (also referred to as estradiol-17/3 dehydrogenase) preferentially catalyzes the reduction of estrone to give the biologically potent estradiol-17,6 and the reduction of 16a-hydroxyestrone to give estriol. Estradiol-17/3 and estriol are the principal estrogens secreted from the syncytiotrophoblast into the maternal circulation during human pregnancy (see reference 1). In addition, a microsomal 17/3-HSD has been identified in human placenta; this membrane-bound enzyme preferentially catalyzes the oxidation of the 17/6-hydroxyl group of estradiol-17,/ and testosterone as well as the 20a-hydroxyl group of 20a-dihydroprogesterone (15) . Recently, Andersson and associates (11) cloned the cDNA for this microsomal form of 17,6-HSD and referred to this isozyme as 17/3-HSD type 2.
The most striking structural difference between the predicted amino acid sequences of 173-HSD types 1 and 2 is an extended hydrophobic amino terminus of the microsomal 17/3-HSD type 2 enzyme, which is believed to correspond to the transmembrane signal anchor. The amino acid sequence of the lumenal portion of 17,6-HSD type 2 shares 23% homology and 45% similarity with 173-HSD type 1 (11 16 (Fig. 4) . The identity of chromosome 16 was confirmed by cohybridization studies using the 17,6-HSD type 2 probe and a chromosome 16-specific centromere probe, D16Z2 (34) (Fig. 4) . From measurements taken in 20 chromosome 16s, it was determined that the 173-HSD type 2 gene is located 89% of the distance from the centromere to the telomere of 16q. This area corresponds to 16q24. Specific signal was detected on chromosome 16 in 57 of 75 metaphase cells evaluated.
Discussion
The results of many studies of 17f.-HSD enzyme activity in a host of tissues from humans and experimental animals are suggestive that there must be several proteins that catalyze oxidation-reduction reactions of steroids at C-17,8 of C18-and C19-steroid substrates and at C-20a of C21-steroids. For example, the apparent Kms of 17,3-HSD(s) for C18-, C19-, and C21-steroids differ by orders of magnitude in some tissues and even in selected subcellular fractions of the same tissue (15, 35, 36) . In addition to steroid substrate specificity, the oxidative pathway of the reaction catalyzed by 17/3-HSD is dominant in some tissues (in the absence of added co-factor [e.g., with intact cells or tissue slices ] ), whereas reduction is more prevalent in others (37) (38) (39) (40) . Furthermore, whereas the reduction pathway is important in the synthesis of the bioactive C18-and C19-steroids, estradiol-173 and testosterone, respectively, the C-20a reduc- tion of progesterone serves, in the human at least, to inactivate this steroid hormone. Contrarily, the preferential oxidation of the C-17fl-hydroxy group gives rise to biologically inactive estrone and androstenedione from estradiol-17f and testosterone, respectively; but, the oxidation of 20a-dihydroprogesterone gives bioactive progesterone. These differences in steroid C-17p6 and C-20a oxidation-reduction cannot be explained singularly by assuming that a given isozyme is localized in steroidogenic tissues and another isozyme is localized in extraglandular tissues. This obtains because the bioactive products of the reduction pathway, e.g., estradiol-17f3, and the oxidative pathway, e.g., progesterone, are preferentially secreted by the same steroidogenic cells in some tissues, e.g., the luteinized granulosa cells of the corpus luteum and the syncytiotrophoblast of the placenta (41 As characterized by Andersson and colleagues (11), 17/-HSD type 2 isozyme preferentially catalyzes the oxidation of estradiol-17#6 to estrone, presumably resulting in a tissue-specific decrease in estrogenic activity. This enzyme also catalyzes the oxidation of testosterone to androstenedione and 20a-dihydroprogesterone to progesterone. These enzyme characteristics are consistent with the proposition that 173-HSD type 2 functions in selected extraglandular tissues to diminish estrogen and androgen action but to preserve the action of progesterone. In the studies of Tseng and Gurpide (19) , the preferential oxidation of 17,l-hydroxy C19-and C18-steroids and C-20a-hydroxy steroids was demonstrated in endometrial tissues. Moreover, this enzyme activity was localized in the glandular epithelium and not in the stroma and the specific activity of 17f-HSD was increased in vivo and in vitro by treatment with progestin (17, 19, 26) . These findings, together with those of this investigation, are supportive of the conclusion that the progestin-stimulated 17/3-HSD of the glandular epithelium of human endometrium is the type 2 isozyme. In addition, progestins act in human endometrium to increase estrone sulfotransferase activity and to decrease the synthesis of estrogen receptors (45) (46) (47) (11) . This difference may be attributable to higher stringency of probing in this study. Indeed, it may be that alternative splicing gives rise to a longer mRNA as is the case for 17,3-HSD type 1. Two forms of 17,6-HSD type 1 mRNAs are present in most tissues: the major form in placenta is 1.3 kb, and a 2.2-kb mRNA with an extended 5 '-noncoding region is present in lower levels in placenta. In addition, it is possible that minor species of mRNA (-2.2 and 1.3 kb) are present in another extraembryonic, non-villous trophoblast tissue (e.g., umbilical cord, amnion, chorion laeve), which may have been present in the tissue/RNA preparation that was used in those studies.
Andersson and colleagues ( 11 ) could not detect 17,3-HSD type 2 mRNA in human prostate and the data obtained in this study also are indicative of very low levels of 17,8-HSD type 2 mRNA in prostate. This is suggestive that an alternate form of 17f3-HSD is expressed in prostate or else that testosterone inactivation in prostate is accomplished primarily by way of the 6ca-or 7a//3-hydroxylation of 5a-androstan-3,6,17,#-diol (11) .
The anatomic distribution of 17,6-HSD isozymes appears to be important in the synthesis of bioactive (17,6- 1713 -HSD isoenzymes will be discovered to account for testosterone synthesis in testis and to account for the conversion of plasma androstenedione to plasma testosterone and of plasma estrone to plasma estradiol-17,# in extragonadal tissues.
